Supartz Side Effects
Generic Name: sodium hyaluronate
Note: This page contains side effects data for the generic drug sodium hyaluronate. It is possible that some of the dosage forms included below may not apply to the brand name Supartz.
It is possible that some side effects of Supartz may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to sodium hyaluronate: injection gel/jelly, injection solution
As well as its needed effects, sodium hyaluronate (the active ingredient contained in Supartz) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking sodium hyaluronate, check with your doctor immediately:Less common
- Blue color or flushing or redness of skin
- difficulty in swallowing
- dizziness or feeling faint (severe)
- redness or pain at place of injection
- skin rash, hives, and/or itching
- stuffy nose
- swelling of eyelids, face, or lips
- tightness in chest, troubled breathing, and/or wheezing
Some sodium hyaluronate side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
- itching of the skin
- large, nonelevated blue or purplish patches in the skin
- loss of appetite
- nausea and/or vomiting
- stomach pain
- swelling of the knee
For Healthcare Professionals
Applies to sodium hyaluronate: intra-articular solution
Most side effects are related to local reactions such as injection site pain, pain, swelling, effusion, or redness of the joint.
Increased risk, severity, or frequency of side effects does not appear to occur with retreatment of sodium hyaluronate (the active ingredient contained in Supartz)
Local side effects for sodium hyaluronate (the active ingredient contained in Supartz) in relation to placebo therapy have included injection site pain (23% vs 13%), joint pain and swelling (13% vs 13%), and local skin reactions consisting of ecchymosis and rash (14% vs 10%) and pruritus (7% vs 4%). Warmth and redness have also been reported.
Injection site pain was listed as the reason for premature discontinuation of treatment in 4% (6/164) of the patients treated with sodium hyaluronate as compared to < 1% (1/164) of placebo-treated patients.
Patients with inflammatory arthritis may experience transient increases in inflammation of the injected knee following treatment.
Hypersensitivity reactions have included 2 cases of anaphylactoid reactions and 3 cases of allergic reactions, which resolved upon discontinuation of sodium hyaluronate (the active ingredient contained in Supartz)
Hypersensitivity side effects have included anaphylactoid reactions and allergic reactions.
Seven cases of fever were reported in one pivotal clinical study. Subsequently, 3 of these cases were reported to be associated with local reactions. No association to pyrogenic arthritis was found.
Other side effects have included fever and headache.
Gastrointestinal side effects for sodium hyaluronate (the active ingredient contained in Supartz) in relation to placebo therapy have included unspecified complaints (29% vs 36%).
Non-specific gastrointestinal complaints were severe in both 4% of patients treated with sodium hyaluronate and 4% of patients treated with placebo.
Cardiovascular side effects have included hypotensive crisis or shock.
There has been one case report of hypotensive crisis or shock, which resolved and did not reoccur with repeated treatment.
Pseudosepsis has been characterized as severe joint inflammation with pain and effusion occurring 24 to 72 hours after injection and it may be more likely to occur after the second or third injection or with repeated courses. Nonsteroidal anti-inflammatory drugs, intra-articular steroids, and/or arthrocentesis are often required to treat pseudosepsis.
In a pivotal clinical study 1.2% (2/164) patients treated with sodium hyaluronate (the active ingredient contained in Supartz) vs. 1.8% (3/164) patients treated with placebo were reported to have a positive bacterial culture of effusion aspirated from the treated knee. Only 1 of the placebo-treated patients required hospitalization for presumptive treatment for septic arthritis. The remaining 4 patients did not show clinical or subsequent signs of infection.
Musculoskeletal side effects have included knee swelling/effusion and pseudosepsis.
More about Supartz (sodium hyaluronate)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.